Use of generics-a critical cost containment measure for all healthcare professionals in europe?

Pharmaceuticals

Volumn 3, Issue 8, 2010, Pages 2470-2494

  Godman, Brian ^a,b,c   Shrank, William ^d   Wettermark, Bjorn ^c   Andersen, Morten ^c   Bishop, Iain ^e   Burkhardt, Thomas ^f   Garuolienè, Kristina ^g,h   Kalaba, Marija ⁱ   Laius, Ott ^j   Joppi, Roberta ^a,k   Sermet, Catherine ^l   Schwabe, Ulrich ^m   Teixeira, Inês ⁿ   Tulunay, F Cankat ^o   Wendykowska, Kamila ^p   Zara, Corinne ^q   Gustafsson, Lars L ^c  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HEALTHCARE IMPROVEMENT SCOTLAND   (United Kingdom)

^f Hauptverband der Österreichischen Sozialversicherungsträger   (Austria)

^g VILNIUS UNIVERSITY   (Lithuania)

^h National Health Insurance Fund   (Lithuania)

ⁱ Republic Institute for Health Insurance   (Serbia)

^j State Agency of Medicines   (Estonia)

^k Pharmaceutical Drug Department   (Italy)

^l IRDES   (France)

^m UNIVERSITY OF HEIDELBERG   (Germany)

ⁿ National Association of Pharmacies (ANF)   (Portugal)

^o ANKARA UNIVERSITY   (Turkey)

^p HTA CONSULTING   (Poland)

^q C Agy Hlth Technol Assess Res   (Spain)

more..

Author keywords

Cost containment; Generic drugs; Generic substitution; Pricing

Indexed keywords

ATORVASTATIN; BENAZEPRIL; CAPTOPRIL; CILAZAPRIL; ENALAPRIL; FOSINOPRIL; GENERIC DRUG; GLIBENCLAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; METFORMIN; OMEPRAZOLE; PROTON PUMP INHIBITOR; QUINAPRIL; RAMIPRIL; RISPERIDONE; SIMVASTATIN;

AMBULATORY CARE; COST CONTROL; DIABETES MELLITUS; DRUG COST; DRUG UTILIZATION; EMBASE; EUROPE; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTERNET; MEDICAL LITERATURE; MEDLINE; OUTCOME ASSESSMENT; PATENT; PATIENT ATTITUDE; PEER REVIEW; PHARMACIST ATTITUDE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; REIMBURSEMENT; REVIEW; UNITED KINGDOM;

EID: 77955576790     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3082470     Document Type: Review

References (98)

1. Simoens, S. The Portuguese generic medicines market: A policy analysis. Pharm. Pract. 2009, 7, 74-80.
2. Simoens, S. Developing competitive and sustainable Polish generic medicines market. Croat. Med. J. 2008, 50, 440-448.
3. Teixeira, I.; Vieira, I. Pharmaceutical Pricing and Reimbursement Information Portugal; Vogler, S., Morak, S., Eds.; Gesundheit Österreich GmbH, Geschäftsbereich Österreichisches Bundesinstitut für Gesund-heitswesen/Austrian Health Institute (GÖG/ÖBIG): Vienna, Austria, 2008; Available online: http://ppri.oebig.at/Downloads/Results/Portugal_PPRI_2008.pdf/ (accessed on 2 March 2010).
4. Sermet, C.; Andrieu, V.; Godman, B.; Van Ganse, E.; Haycox, A.; Reynier, J.P. Ongoing pharmaceutical reforms in France; considerations for other countries and implications for key stakeholder groups in France. Appl. Health Econ. Health Policy 2010, 8, 7-24.
5. Wettermark, B.; Godman, B.; Andersson, K.; Gustafsson, L.L.; Haycox, A.; Bertele, V. Recent national and regional drug reforms in Sweden-Implications for pharmaceutical companies in Europe. Pharmacoeconomics 2008, 26, 537-550.
6. Godman, B.; Bucsics, A.; Burkhardt, T.; Haycox, A.; Seyfried, H.; Wieninger, P. Insight into recent reforms and initiatives in Austria; implications for key stakeholders. Expert Rev. Pharmacoecon. Outcomes Res. 2008, 8, 357-371.
7. Heikkilä, R.; Mäntyselkä, P.; Hartikainen-Herranen, K.; Ahonen, R. Customers' and physicians' opinions of experiences with generic substitution during the first year in Finland. Health Policy 2007, 82, 366-374.
8. Orzella, L.; Chini, F.; Rossi, P.; Borgia, P. Physician and patient characteristics associated with prescriptions and cost of drugs in the Lazio region of Italy. Health Policy 2010, 95, 236-244.
9. Tsiantou, V.; Zavras, D.; Kousoulakou, H.; Geitona, M.; Kyriopoulos, J. Generic medicines: Greek physicians' perceptions and prescribing policies. J. Clin. Pharm. Therapeut. 2009, 34, 547-554.
10. Garattini, L.; Motterlini, N.; Cornago, D. Prices and distribution margins of in-patent drugs in pharmacy: A comparison in seven European countries. Health Policy 2008, 85, 305-313.
11. Godman, B.; Wettermark, B.; Hoffman, M.; Andersson, K.; Haycox, A.; Gustafsson, L.L. type=contributor>Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden; Global relevance. Expert Rev. Pharmacoecon. Outcomes Res. 2009, 9, 65-83.
12. Comma, A.; Zara, C.; Godman, B.; Augusti, A.; Diogene, E.; Wettermark, B.; Haycox, A. Policies to enhance the efficiency of prescribing in the Spanish Catalan Region: Impact and future direction. Expert Rev. Pharmacoecon. Outcomes Res. 2009, 9, 569-581.
13. Schneeweiss, S.; Walker, A.; Glynn, R.; Maclure, M.; Dortmuth, C.; Soumerai, S. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. NEJM 2002, 346, 822-829.
14. Schneeweiss, S.; Dortmuth, C.; Grootendorst, P.; Soumerai, S.; Maclure, M. Net Health Plan Savings From Reference Pricing for Angiotensin-Converting Enzyme Inhibitors in Elderly British Columbia Residents. Med. Care 2004, 42, 653-660.
15. Cameron, A.; Ewen, M.; Ross-Degnan, D.; Ball, D.; Laing, R. Medicine prices, availability and affordability in 36 developing and middle-income countries: A secondary analysis. Lancet 2009, 273, 240-249.
16. Simoens, S. Generic medicine pricing in Europe: Current issues and future perspective Jpn. Med. Econom. 2008, 11, 171-175.
17. Seeley, E.; Kanavos, P. Generic medicines from a societal perspective: Savings for health care systems. Eurohealth 2008, 14, 18-22.
18. Seeley, E. Maximising the benefits from generic competition. Euro. Observ. 2008, 10, 8-11.
19. Simoens, S. Trends in generic prescribing and dispensing in Europe. Expert Rev. Clin. Pharmacol. 2008, 1, 497-503.
20. Simoens, S. International comparison of generic medicine prices. Curr. Med. Res. Opin. 2007, 23, 2647-2654.
21. Figueiras, M.; Alves, N.; Marcelino, D.; Cortes M.; Weinman J.; Horne, R. Assessing lay beliefs about generic medicines: Development of the generic medicines scale. Psychol. Health Med. 2009, 14, 311-321.
22. Kesselheim, A.; Stedman, M.; Bubrick, E.; Gagne, J.; Misono, A.; Lee, J.; Brookhardt, A.; Avron, J.; Shrank, W. Seisure outcomes following the use of generic vs. brand-name antiepileptic drugs. A systematic review and meta-analysis. Drugs 2010, 70,605-621
23. Chua, G.; Hassali, M.; Shafie, A.; Awaisu, A. A survey exploring knowledge and perceptions of general practitioners towards the use of generic medicines in the northern state of Malaysia. Health Policy 2010, 95, 229-325
24. European Commission. Communication from the Commission-Executive Summary of the Pharmaceutical Sector Inquiry Report. Reference EU Commission report. 8 July 2009. Available online: http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/communication_en.pdf/ (accessed on 30 May 2010).
25. Ferner, R.; Lenney, W.; Marriott, J. Controversy over generic substitution. BMJ 2010, 340, 1341-1343.
26. Price falls are following a familiar pattern. Generics Bull. 2010. Available online: http://www.- wavedata.co.uk/btn/generics%20bulletin/0000-60%20Price%20falls%20are%20following-%20a%20familiar%20pattern%2028%20May%202010.pdf/ (Accessed on 24 June 2010).
27. McGinn, D.; Godman, B.; Lonsdale, J.; Way, R.; Wettermark, B.; Haycox, A. Initiatives to enhance the efficiency of statin and proton pump inhibitor prescribing in the UK: Impact and implications. Expert Rev. Pharmacoecon. Outcomes Res. 2010, 10, 73-85.
28. Godman, B.; Schwabe, U.; Selke, G.; Wettermark, B. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of Proton Pump Inhibitors and lipid-lowering drugs. Pharmacoeconomics 2009, 27, 1-4.
29. Godman, B.; Haycox, A.; Schwabe, U.; Joppi, R.; Garattini, S. Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 2008, 26, 91-98.
30. Perry, G. The European generic pharmaceutical market in review: 2006 and beyond. Jpn. Gener. Med. 2006, 4, 4-14.
31. Figueiras, M.; Marcelion, D.; Cortes, M. People's views on the level of agreement of generic medicines for different illneses. Pharm. World Sci. 2008, 30, 590-594.
32. Bland, B. Indonesian doctors are told to prescribe more generic drugs to reduce escalating health costs. BMJ 2010, 340, c349.
33. Simoens, S. Interchangeability of off-patent medicines: A pharmacoeconomic perspective. Expert Rev. Pharmacoecon. Outcomes Res. 2008, 8, 519-521.
34. Shrank, W.; Cox, E.; Fischer, M.; Mehta, J.; Choudry, N. Patients' perception of generic medications. Health Affair 2009, 28, 546-556.
35. Kohl, H.; Shrank, W. Increasing generic drug us in Medicare Part D: The role of government. JAGS 2007, 55, 1108-1109.
36. Godman, B.; Wettermark, B. Impact of reforms to enhance the quality and efficiency of statin prescribing across 20 European countries. In The 9th Congress of the European Association for Clinical Pharmacology and Therapeutics, Edinburgh, Scotland, 12-15 July 2009; pp. 65-69.
37. Godman, B.; Wettermark, B. Trends in consumption and expenditure of proton pump inhibitors (PPIs) in 20 European countries. In The 9th Congress of the European Association for Clinical Pharmacology and Therapeutics, Edinburgh, Scotland, 12-15 July 2009; pp. 71-75.
38. Garattini, S.; Bertele, V.; Godman, B.; Haycox, A.; Wettermark, B.; Gustafsson, L.L. Enhancing the rational use of new medicines across European healthcare systems-A Position Paper. Eur. J. Clin. Pharmacol. 2008, 64, 1137-1138.
39. Lee, T.; Emanuel, E. Tier 4 drugs and the fraying of the social compact. NEJM 2008, 359, 333-335.
40. Wettermark, B.; Persson, M.E.; Wilking, N.; Kalin, M.; Korkmaz, S.; Hjemdahl, P.; Godman B.; Petzold, M.; Gustafsson, L.L. Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Serv. Res. 2010, 10, 128.
41. Shrank, W.; Cadarette, S.; Cox, E.; Fischer, M.; Metha, J.; Brookhardt, A.; Avron, J.; Choudry, N. Is there a relationship between patient beliefs or communication about generic drugs and medication utilization? Med. Care 2009, 47, 1-7.
42. Kanavos, P. Generic policies: Rhetoric vs. reality. Euro. Observ. 2008, 10, 1-6.
43. Kjoenniksen, I.; Lindbaek, M.; Grannas, A. Patients' attitudes towards and experiences of generic drug substitution in Norway. Pharm. World Sci. 2006, 28, 284-289.
44. Himmel, W.; Simmenroth-Nayada, A.; Niebling, W.; Ledig, T.; Jansen, R.D.; Kochen, M.M.; Gleiter, C.H.; Hummers-Pradier, E. What do primary care patients think about generic drugs? J. Clin. Pharmacol. Ther. 2005, 43, 472-479.
45. Generic drugs: Protest group was not quite what it seemed. BMJ 2010, 340, c1514.
46. Kesselheim, A.; Misoni, A.; Lee, J.; Stedman, M.; Brookhardt, M.; Choudry, N.; Shrank, W. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease-A systematic review and meta-analysis. JAMA 2008, 300, 2514-2526.
47. Mofsen, R.; Balter, J. Case reports of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation. Clin. Ther. 2001, 23, 1720-1731.
48. Alvarez, C.A.; Mascarenas, C.; Timmerman, I. Increasing psychosis in a patient switched from Clozaril to generic clozapine. Am. J. Psychiat. 2006, 163, 746.
49. Healy, D.J.; Taylor, S.; Goldman, M.; Barry, K.; Blow, F.; Milner, K.K. Clinical equivalence of generic clozapine. Community Ment. Health J. 2005, 41, 393-398.
50. Alessi-Severini, S.; Honcharik, PL.; Simpson, K.D.; Eleff, M.K.; Collins, D.M. Evaluation of an interchangeability switch in patients treated with clozapine: A retrospective review. J. Clin. Psychiat. 2006, 67, 1047-1054.
51. Paton, C. Generic clozapine: Outcomes after switching. Br. J. Psychiat. 2006, 89, 184-185.
52. Bazire, S.; Burton, V. Generic clozapine in schizophrenia: What is all the fuss about? Pharm. J. 2004, 173, 720-721.
53. Araszkiewicz, A.A.; Szabert, K.; Godman, B.; Wladysiuk, M.; Barbui, C.; Haycox, A. Generic olanzapine: Health authority opportunity or nightmare? Expert Rev. Pharmacoecon. Outcomes Res. 2008, 8, 549-555.
54. Jack, A. Balancing Big Pharma's books. BMJ 2008, 336, 418-419.
55. Sturm, H.; Austvoll-Dahlgren, A.; Aaserud, M.; Oxman, A.D.; Ramsay, C.; Vernby, Å.; Kösters, J.P. Pharmaceutical policies: Effects of financial incentives for prescribers (Review). Cochrane Database Syst. Rev. 2007, 3, doi: 10.1002/14651858.CD006731.
56. World Health Organisation (WHO). Guidelines for ATC Classification and DDD Assignment 2009. WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway, 2009; www.whocc.no/ (accessed on 15 January 2010).
57. Studies in Drug Utilization-Methods and Applications; Bergman, U., Gimsson, A., Wahba, A., Westerholm, B., Eds.; World Health Organization Regional Publications: Copenhagen, Denmark, 1979.
58. World Health Organization. The Selection of Essential Drugs; Technical Report Series No. 615; World Health Organization: Geneva, Switzerland, 1977.
59. World Health Organization. Introduction to Drug Utilisation Research; WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services: Geneva, Switzerland,2010; Available online: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/Drug%20utilization%20research.pdf/ (accessed on 30 January 2010).
60. Walley, T.; Folino-Gallo, P.; Schwabe, U.; Van Ganse, E. Variations and increase in use of statins across Europe: Data from administrative databases. BMJ 2004, 328, 385-386.
61. Vlahović-Palcevski, V.; Gantumur, M.; Radoševic, N.; Palčevski, C.; Vander Stichele, R. Coping with changes in the Defined Daily Dose in a longitudinal drug consumption database. Pharm. World Sci. 2010, 32, 125-129.
62. Walley, T.; Folino-Gallo, P.; Stephens, P.; Van Ganse, E. Trends in prescribing and utilisation of statins and other lipid lowering drugs across Europe 1997-2003. Br. J. Clin. Pharmacol. 2005, 60, 543-551.
63. Germed. Una Peticion Historica; 7 December 2009. Available online: http://www.germed.es/71220092.htm/ (accessed on 10 June 2010).
64. Chaplin, S.; Duerden, M. When Brands Are Best-Brand vs. Generic Prescribing; Wiley Interface Ltd.: Hoboken, NJ, USA, 2006.
65. Duerden, M. Making sense of drug pricing. Prescriber Supplement; John Wiley & Sons Ltd.: Chichester, UK; 2006; pp. 1-5.
66. Office of Fair Trading (UK). The Pharmaceutical Price Regulation System: An OFT Study. Annexe A: Market for Prescription Pharmaceuticals in the NHS; The Office of Fair Trading: London, UK, 2007; Available online: http://www.oft.gov.uk/shared_oft/reports/comp_policy/oft885a.pdf/ (Accessed Mar 3 2010).
67. Coombes, R. GPs saved £400m in 2008 by increasing use of generic drugs. BMJ 2009, 338, 1230.
68. Hughes, D.; Ferner, R. New drugs for old: disinvestment and NICE. BMJ 2010, 340, 690-692.
69. Consultez l'accord national sur les génériques et ses avenants. Available online: http://www.ameli.fr/professionnels-de-sante/pharmaciens/votre-convention/textes/accordnational- sur-les-generiques/index.php (Accessed 28 June 2010).
70. Médicaments génériques: plus d'1 milliard d'euros d'économie en 2009. Available online: http://www.ameli.fr/fileadmin/user_upload/documents/CP_generiques_nov_09_vdef.pdf/ (Accessed 28 June 2010).
71. Norman, C.; Zarrinkoub, R.; Hasselström, J.; Godman, B.; Granath, F.; Wettermark, B. Potential savings without compromising the quality of care. Int. J. Clin. Pract. 2009, 63, 1320-1326
72. Agenzia Italiana del Farmaco. Osmed Database Reports 2007 and 2008; Available online: http://www.agenziafarmaco.it/it/content/rapporti-osmed-luso-dei-farmaci-italia/ (Accessed 24 May 2010).
73. Usher-Smith, J.A.; Ramsbottom, T.; Pearmain, H.; Kirby, M. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candersartan in a Primary care setting. Int. J. Clin. Pract. 2007, 61, 15-23.
74. Usher-Smith, J.; Ramsbottom, T.; Pearmain, H.; Kirby, M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int. J. Clin. Pract. 2008, 62, 480-484.
75. Moon J, Bogle R. Switching statins - Using generic simvastatin as first line could save £2bn over five years in England. BMJ 2006, 332, 1344-1345.
76. Gumbs, P.; Verschuren, W.; Souverein, P.; Mantel-Tuwisse, A.; de Wit, A.; de Boer, A.; Klungel, K. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. Br. J. Clin. Pharmacol. 2007, 64, 680-685.
77. Wettermark, B.; Godman, B.; Jacobsson, B.; Haaijer-Ruskamp, F. Soft regulations in pharmaceutical policymaking - an overview of current approaches and their consequences. Appl. Health Econ. Health Policy 2009, 7, 1-11.
78. Adamski, J.; Godman, B.; Ofierska-Sujkowska, G.; Osinska, B.; Herholz, H.; Wendykowska, K.; Laius, O.; Jan, S.; Sermet, C.; Zara, C; Kalaba, M; Gustafsson, R; Garuolienè, K; Haycox, A; Garattini, S; Gustafsson, L.L. Review of risk sharing schemes for pharmaceuticals: considerations, critical evaluation and recommendations for European payers. BMC Health Serv. Res. 2010, 10, 153.
79. Versantvoort C, Maliepaard M, Lekkerkerker F. Generics: what is the role of authorities. Neth. J. Med. 2008, 66, 62-66.
80. British National Formulary. Available online: http://bnf.org/bnf/index.htm/ (Accessed 3 March 2010).
81. Simoens, S. Health economics of market access for biopharmaceuticals and biosimilars. J. Med. Econom. 2009, 12, 211-218.
82. Toth, F. Healthcare policies over the last 20 years: reforms and counter-reforms. Health Policy 2010, 95, 82-89.
83. Kopp, C.; Vandevelde, F. Use of International Nonproprietary names (INN) among members. ISDB Newsletter 2006, 20, 2-4.
84. Kanavos P. Do generics offer significant savings to the UK National Health Service? Curr. Med. Res. Opin. 2007, 23, 105-116.
85. Wettermark, B.; Pehrsson, A.; Juhasz-Haverinen, M.; Veg, A.; Edlert, M.; Törnwall-Bergendahl, G.; Almkvist, H.; Godman, B.; Granath, F.; Bergman, U. Financial incentives linked to selfassessment of prescribing patterns - a new approach for quality improvement of drug prescribing in primary care. Qual. Primary Care 2009, 17, 179-189.
86. Godman, B., Burkhardt, T, Bucsics, A.; Wettermark, B.; Wieninger, P. Impact of recent reforms in Austria on utilisation and expenditure of PPIs and lipid lowering drugs; implications for the future. Expert Rev Pharmacoecon. Outcomes Res. 2009, 9, 475-484.
87. Directive 2004/27/EC of the European Parliament and of the Council of 31st March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official J. Eu. 2006, L 136, 34-57.
88. Puig-Junoy, J. Politicas de fomento de la competencia en precios en el mercado de genericos: leccines de la experiencia europea. Gac. Sanit. 2010, 24, 193-199.
89. Festoy, H.; Sveen, K.; Yu, L.-M.; Gjonnes, L.; Gregersen, T. Norway - Pharmaceutical Pricing and Reimbursement Information; October 2008. Available online: http://ppri.oebig.at/Downloads/ Results/Norway_PPRI_2008.pdf/ (Accessed 3 June 2010).
90. Schreyögg, J.; Henke, K.-D.; Busse, R. Managing Pharmaceutical Regulation in Germany. Discussion Paper; Technische Universität Berlin, Fakultät Wirtschaft und Management: Berlin, Germany, 2004.
91. Antoňanzas, F.; Oliba, J.; Pinillos, M.; Juàrez. C. Economic aspects of the new Spanish laws on pharmaceutical preparations. Eur. J. Health Econ. 2007, 8, 297-300.
92. Godman, B.; Bucsics, A.; Burkhardt, T.; Schmitzer, M.; Wettermark, B.; Wieninger, P. type=contributor>Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries. Expert Rev. Pharmacoecon. Outcomes Res. 2010, 10, 199-207.
93. Garattini, L.; Ghislandi, S. Off-patent drugs in Italy: a short sighted view? Eur. J. Health Econ. 2006, 7, 79-83.
94. Ghislandi, S.; Krulichova, I.; Garattini, L. Pharmaceutical policy in Italy: towards a structural change? Health Policy 2005, 72, 53-63.
95. Rocchi, F.; Addis, A.; Martini, N. Current national initiatives about drug policies and cost control in Europe: the Italy example. J. Ambulatory Care Manage. 2004, 27, 127-131.
96. Wessling, A.; Lundin, D. The Review of Drugs against Disease Caused by Acid Stomach - a Summary; Pharmaceuticals Benefits Board: Solna, Sweeden, 2006. Available online: http://www.tlv.se/Upload/Genomgangen/summary-stomach-acid.pdf/ (Accessed 5 May 2010).
97. Taylor, L. New UK PPRS includes 3.9% price cut, flexible pricing and generic substitution. 20 November 2008. Available online: http://www.eatg.org/eatg/Global-HIV-News/Access-totreatment/ New-UK-PPRS-includes-3.9-price-cut-flexible-pricing-and-generic-substitution/ (Accessed 3 May 2010).
98. Anon. Better Care Better Value Indicator. Low cost PPI prescribing. Available online: http://www.productivity.nhs.uk/Def_IncreasingLowCostPPIPrescribing.aspx/ (Accessed 3 May 2010).